All Articles

Hadron Energy unveils an all-star board for its $1.2B public listing, betting its micro-nuclear reactors can solve the AI industry's energy crisis.

With Canada's first natural hydrogen well at a critical juncture, MAX Power installs a clean energy veteran to shift from pure exploration to production.

Coveo's new RAG-as-a-Service for AWS aims to fix AI's 'hallucination' and security issues, unlocking enterprise value and reshaping the cloud AI market.

With a new VP and a unique bank-powered platform, Cornerstone Capital Bank aims to capture market share amidst complex regulations and a shifting economy.

A UK-US team has unlocked a scalable method to create nuclear fuel from americium, paving the way for long-duration missions to the Moon and deep space.

With FDA alignment on a biomarker-driven trial, Cognition's zervimesine aims to reshape Alzheimer's treatment with a convenient, targeted oral therapy.

Facing financial headwinds, Treasure Global projects explosive growth through a high-stakes pivot into fintech. Can this strategic gamble pay off?

Medtech firm Kestra Medical seeks new capital to scale its wearable defibrillator, signaling a major push in the competitive cardiovascular tech market.

Teramind’s new AI co-pilot replaces security dashboards with simple Slack chats. This isn't just an update; it's a new era for managing insider risk.

As ProQR prepares for its Evercore chat, investors weigh the promise of its unique RNA editing platform against a field of biotech giants.

A new antisense therapy, zorevunersen, shows disease-modifying potential, shifting focus from seizure control to tackling the genetic root of the disease.

A major REIT's acquisition of Village Pointe signals more than a transaction; it's a vote of confidence in Omaha and the future of lifestyle centers.

John D. Steinmetz's national award spotlights Vista Bank's meteoric rise and a pivotal merger, signaling a major shift in the regional banking landscape.

A global engineering giant just acquired a key Australian firm. We explore how this move positions it to dominate a multi-billion dollar market.

A renewable energy company's leap into mining raises questions. Is it brilliant vertical integration or a high-risk gamble diluting its green mission?

Beyond the hire, Coalition's new product chief from Nubank signals a strategic bet on proactive prevention over reactive payout in the war on digital risk.

At ASH 2025, Bristol Myers Squibb didn't just show new drugs; it unveiled a powerful strategy combining cell therapy and protein degradation.

With staggering revenue growth, key partnerships, and a TSX uplisting, this food-tech innovator is disrupting the global food supply chain.

ProMIS Neurosciences' bet on plasma pTau could make Alzheimer's trials faster and cheaper, giving its unique drug PMN310 a critical edge.

Post's new $1.3B bond deal extends its debt maturity but at a higher cost. We analyze the market's mixed reaction and what it means for future growth.